GLPwatch
[Glucagon-like peptide-1: a cardiological perspective].
Ugeskr Laeger · 2010
Last updated 2026-05-28Research suggests GLP-1 and its medications may directly benefit the heart by improving blood flow, reducing heart muscle damage after a heart attack, and strengthening a weakened left ventricle. Small patient studies have supported these findings, and the effect of protecting heart muscle after a blocked artery is reopening is highlighted as a promising area for further testing.
AI summary of the abstract below.
| Journal | Ugeskr Laeger, 2010 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Cardiovascular Risk Reduction, Type 2 Diabetes, Obesity |
Abstract
Increasing experimental evidence points to direct effects of glucagon-like peptide-1 (GLP-1) and its analogs on the heart and circulatory system, in addition to the well-established, antidiabetic actions of these agents on glucose and on the energy metabolism. These effects are primarily vasodilation, diminished heart muscle loss after myocardial infarction and a contractility increase of a weak left ventricle. A few, small patient trials appear to support the latter effect. Experimental results suggest the myocardium-saving effect following coronary occlusion and reperfusion as particularly suitable for clinical testing.
Verbatim abstract via PubMed 20961501 ↗